Publications by authors named "Quivrin M"

Background: Nodes are the second site for prostate cancer recurrence. Whole-pelvic radiotherapy (WPRT) has shown superiority over nodal stereotactic body radiotherapy (SBRT) in two retrospective cohorts. We aimed to compare both modalities and assess factors associated with treatment outcomes.

View Article and Find Full Text PDF

Background And Objective: Darolutamide is an androgen receptor inhibitor that increases overall survival in combination with androgen deprivation therapy (ADT) in patients with metastatic hormone-sensitive and nonmetastatic castration-resistant prostate cancer (PCa). This phase 2 study assessed the efficacy and safety of darolutamide as monotherapy without ADT in patients with eugonadal testosterone levels.

Methods: This was a 24-wk, open-label, randomized study of patients with hormone-sensitive, histologically confirmed PCa requiring gonadotropin-releasing hormone (GnRH); an Eastern Cooperative Oncology Group performance status score of 0/1; and life expectancy >1 yr.

View Article and Find Full Text PDF

Left ventricular assist device (LVAD) implantation is an established treatment for patients with advanced heart failure refractory to medical therapy. However, the incidence of ventricular arrhythmias (VAs) is high in this population, both in the acute and delayed phases after implantation. About one-third of patients implanted with an LVAD will experience sustained VAs, predisposing these patients to worse outcomes and complicating patient management.

View Article and Find Full Text PDF

Background: Immunotherapy targeting the PD-1/PD-L1 pathway is a standard of care in a number of metastatic malignancies, but less than a fifth of patients are expected to respond to ICIs (Immune Checkpoint Inhibitors). In a clinical trial, combining the anti-TIGIT (T cell immunoreceptor with Ig and ITIM domains) Mab (monoclonal antibody) tiragolumab with atezolizumab improved outcomes in non-small cell lung cancer. In preclinical models, SBRT (Stereotactic Body Radiation Therapy) could increase expression levels of the inhibitory co-receptors TIGIT and PD-L1.

View Article and Find Full Text PDF

Purpose: Little is known about whether baseline health-related quality of life (HRQoL) scores also could predict occurrence radiotherapy-related toxicities, which we aim to assess in this study.

Methods: This study analyzed data from 200 patients enrolled in randomized study investigating the utility of HRQoL. HRQOL was assessed at baseline and during follow up using QLQ-C30 questionnaire and major toxicity was considered as adverse event ≥ 3 according to NCI-CTCAE classification.

View Article and Find Full Text PDF
Article Synopsis
  • - The study investigates how inflammation, represented by neutrophil-to-lymphocyte ratio (NLR) and neutrophil count (PNN), impacts survival outcomes in patients with localized bladder cancer undergoing chemoradiation.
  • - Analyzed data from 194 patients showed that those with high NLR (above 2.6) and elevated PNN (above 4000/mm) experienced significantly lower overall survival (OS) and progression-free survival (PFS).
  • - While high PNN was a strong indicator of poor OS and PFS outcomes, NLR did not prove to be an independent prognostic factor in this analysis.
View Article and Find Full Text PDF
Article Synopsis
  • - Patients with oligometastatic prostate cancer (having up to 5 metastases) generally have a better prognosis than those with more extensive disease, making this a crucial area for treatment investigation.
  • - The study investigates whether combining stereotactic body radiotherapy (SBRT) with the immune checkpoint inhibitor durvalumab can improve progression-free survival in these patients compared to SBRT alone.
  • - This multicenter phase II trial will evaluate various outcomes, including quality of life and immune response, by enrolling 96 participants over three years, aiming to provide insights into better treatment strategies for prostate cancer.
View Article and Find Full Text PDF
Article Synopsis
  • The study investigates the effectiveness and safety of stereotactic body radiation therapy (SBRT) as a salvage treatment for prostate cancer recurrence after previous radiation therapy, focusing on determining the best dosing regimen.
  • It included 21 patients with specific cancer characteristics, delivering either five or six doses of 6 Gy, and monitored for any severe side effects in the first 18 weeks post-treatment.
  • Results showed no severe complications, and while some patients experienced mild genitourinary issues, all were alive and cancer-free during the follow-up, leading to a recommendation for the 6 × 6 Gy dosage to advance further studies.
View Article and Find Full Text PDF
Article Synopsis
  • Radiotherapy dose escalation, specifically through the addition of high dose-rate brachytherapy (HDR-BB), has been shown to enhance biochemical control in patients with intermediate- to high-risk prostate cancer, as validated by this study involving 709 patients.* -
  • After a median follow-up of 62 months, the results revealed a 5-year biochemical control rate of 87.5%, with 91% for intermediate-risk and 85% for high-risk categories, alongside high rates of clinical relapse-free survival and overall survival.* -
  • The study concluded that HDR-BB is effective and well-tolerated when used with external beam radiotherapy, and suggests that integrating new hormonal treatments or refined fractionation regimens could
View Article and Find Full Text PDF

Purpose: The optimal salvage pelvic treatment for nodal recurrences in prostate cancer is not yet clearly defined. We aimed to compare outcomes of salvage involved-field radiation therapy (s-IFRT) and salvage extended-field radiation therapy (s-EFRT) for positron emission tomography/computed tomography-positive nodal-recurrent prostate cancer and to analyze patterns of progressions after salvage nodal radiation therapy.

Methods And Materials: Patients with F-fluorocholine or Ga prostate-specific membrane antigen ligand positron emission tomography/computed tomography-positive nodal-recurrent prostate cancer and treated with s-IFRT or s-EFRT were retrospectively selected.

View Article and Find Full Text PDF

Background: Magnetic resonance-guided radiotherapy (MRgRT) utilization is rapidly expanding, driven by advanced capabilities including better soft tissue imaging, continuous intrafraction target visualization, automatic triggered beam delivery, and the availability of on-table adaptive replanning. Our objective was to describe patterns of 0.35 Tesla (T)-MRgRT utilization in Europe and Asia among early adopters of this novel technology.

View Article and Find Full Text PDF

The impact of routine assessment of health-related quality of life (HRQoL) on satisfaction with care and the HRQoL of patients with head and neck cancer (HNC) treated with radiotherapy was assessed. Patients with HNC were randomly assigned to two arms, with stratification on sex, cancer localization, and stage of the disease. In the intervention arm, the patients completed the EORTC QLQ-C30 and EORTC QLQ-H&N35 questionnaires first before randomization, then before each medical appointment during radiotherapy (7 weeks), and then every 3 months until 1 year and at 2 years thereafter.

View Article and Find Full Text PDF

External beam radiation therapy (EBRT) can cure localized prostate cancer (PCa) by sterilizing cancer cells in the prostate gland and surrounding tissues at risk of microscopic dissemination. We hypothesized that pelvic EBRT for localized PCa might have an unexpected prophylactic impact on the occurrence of pelvic bone metastases. We reviewed the data of 332 metastatic PCa patients.

View Article and Find Full Text PDF

Purpose: The concept of metastasis-directed therapy for nodal oligorecurrences with stereotactic body radiotherapy is increasingly accepted. Hence, the comparison between salvage extended field radiotherapy (s-EFRT) and salvage involved field radiotherapy (s-IFRT) in patients with F-fluorocholine (FCH) PET/CT+ nodal oligorecurrences from prostate cancer is worthy of investigation.

Methods: Patients with oligorecurrent nodes on FCH PET/CT treated with salvage radiotherapy between 2009 and 2017 in a single tertiary cancer centre were selected for this study.

View Article and Find Full Text PDF
Article Synopsis
  • The study aimed to assess the dose distribution of additional radioactive seeds implanted during salvage permanent prostate implant (sPPI) after an initial permanent prostate implant (pPPI).
  • Patients were evaluated using CT scans taken 30 days after the initial implant and again after an average of six years following sPPI, with comparisons made between the initial and modified CT for dosimetric analysis.
  • Results showed significant differences in radiation dose and volume metrics after the sPPI, indicating that the remaining primary seeds can affect the dosimetric evaluation and should be accounted for in assessments.
View Article and Find Full Text PDF

The treatment of local recurrence of a previously irradiated cancer or a second cancer arising in-field remains challenging. Ultimately, the objective of salvage therapy is to control disease while ensuring minimal collateral damage, thereby optimizing both cancer and toxicity outcomes. Reirradiation has historically been associated with unacceptable toxicity and a limited benefit.

View Article and Find Full Text PDF

Introduction: Prostate requires a daily correction of its 3-dimensional position in relation with rectal distension. In this study, we sought to determine whether rectal distension with respect to the rectal behavior might have an impact on prostate translations and/or rotations during prostate image guided radiation therapy using a 6 degrees-of-freedom (DOF) couch.

Methods And Materials: We reviewed the data from 39 patients with localized prostate cancer treated with protracted external radiation therapy using a 6 DOF couch.

View Article and Find Full Text PDF

Background And Purpose: To evaluate the influence of delays for radiotherapy on survival, recurrence and upstaging for head and neck squamous-cell carcinoma (HNSCC) with no nodal involvement treated with intensity modulated radiotherapy (IMRT).

Material And Methods: This retrospective study included 63 consecutive patients with HNSCC located in the pharynx and larynx and treated with exclusive IMRT with or without chemotherapy. Survival, loco-regional or distant failure and upstaging were analyzed according to the waiting time.

View Article and Find Full Text PDF

Purpose: Salvage prostate permanent implant (sPPI) for postradiation local failure provides high rates of biochemical control. The cumulative dose delivered to the prostate and the rectum is still unknown.

Methods And Materials: We reviewed the postimplant CT-based dosimetry of 18 selected patients who underwent sPPI with (125)I seeds for isolated biopsy-proven local failure several years after external beam radiation therapy.

View Article and Find Full Text PDF

Purpose: To determine whether post-implant MRI-based dosimetry of the Dominant Intra-prostatic Lesion (DIL) could best predict the occurrence of PSA bounce after prostate brachytherapy.

Methods And Materials: We selected 66 patients with a low risk prostate cancer treated with (125)I prostate brachytherapy as monotherapy. Post-implant dosimetry based on day 30 CT-scan and multiparametric MRI co-registration was generated: planned D90, D95, V100, V150 values were calculated for each DIL.

View Article and Find Full Text PDF

Background And Purpose: We aimed to evaluate the patterns of loco-regional failure (LRF) after exclusive chemoradiotherapy (eCRT) for esophageal cancer with respect to planned dose and/or the incidental (unplanned) dose outside target volumes.

Materials And Methods: Co-image registration of CT or (18)F-FDG PET-CT at the time of failure (tf) and at the time of CRT (t0) was performed in 34 patients with LRF. Dosimetric parameters with regard to local failure (LF), nodal failure (NF) and involved nodal stations (NS) were derived.

View Article and Find Full Text PDF

Esophageal cancer has a high likelihood of distant lymphatic spread even at an early stage. Radiotherapy plays a major role in the management of localized or locally-advanced esophageal cancer with a regional or distant lymph node involvement. Radiotherapy can sterilize micrometastatic nodes and cancer cells in transit in the peri-esophageal fat that are not removed by surgery.

View Article and Find Full Text PDF

Background: To evaluate the feasibility and efficacy of Stereotactic body radiation therapy (SBRT) for primary liver lesions and liver metastases treated with linear accelerators with or without rotational Intensity Modulated RadioTherapy (IMRT).

Methods: Patients with either hepatocellular carcinoma, cholangiocarcinoma or metastatic liver lesions who had one to three lesions treated with SBRT in a single institution were retrospectively reviewed. Tumor response was evaluated according to EASL criteria 3 months after SBRT completion using MRI and/or abdominal CT scan.

View Article and Find Full Text PDF

Due to its increasing incidence and a grim prognosis, primary liver cancer remains a diagnostic and therapeutic challenge. For small localized tumors, surgical resection and liver transplantation are standard treatments with a curative-intent. Therapeutic options for locally advanced or metastatic diseases are limited.

View Article and Find Full Text PDF